150 related articles for article (PubMed ID: 27440071)
21. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
[TBL] [Abstract][Full Text] [Related]
22. Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin.
Sheoran AS; Artiushin S; Timoney JF
Vaccine; 2002 Feb; 20(11-12):1653-9. PubMed ID: 11858875
[TBL] [Abstract][Full Text] [Related]
23. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
Mansour NM; Abdelaziz SA
Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
[TBL] [Abstract][Full Text] [Related]
24. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
25. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
26. Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine.
Kotloff KL; Wasserman SS; Jones KF; Livio S; Hruby DE; Franke CA; Fischetti VA
Infect Immun; 2005 Apr; 73(4):2360-6. PubMed ID: 15784582
[TBL] [Abstract][Full Text] [Related]
27. A dual-adjuvanting strategy for peptide-based subunit vaccines against group A Streptococcus: Lipidation and polyelectrolyte complexes.
Zhao L; Yang J; Nahar UJ; Khalil ZG; Capon RJ; Hussein WM; Skwarczynski M; Toth I
Bioorg Med Chem; 2020 Dec; 28(24):115823. PubMed ID: 33120079
[TBL] [Abstract][Full Text] [Related]
28. The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.
Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Med Chem; 2016; 13(1):22-27. PubMed ID: 27449794
[TBL] [Abstract][Full Text] [Related]
29. Moving forward: a mucosal vaccine against group A streptococcus.
Georgousakis MM; McMillan DJ; Batzloff MR; Sriprakash KS
Expert Rev Vaccines; 2009 Jun; 8(6):747-60. PubMed ID: 19485755
[TBL] [Abstract][Full Text] [Related]
30. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
[TBL] [Abstract][Full Text] [Related]
31. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
[TBL] [Abstract][Full Text] [Related]
32. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
33. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I
J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857
[TBL] [Abstract][Full Text] [Related]
34. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
[TBL] [Abstract][Full Text] [Related]
35. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.
Georgousakis MM; Hofmann A; Batzloff MR; McMillan DJ; Sriprakash KS
Vaccine; 2009 Nov; 27(48):6799-806. PubMed ID: 19729086
[TBL] [Abstract][Full Text] [Related]
36. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS).
Rivera-Hernandez T; Hartas J; Wu Y; Chuan YP; Lua LH; Good M; Batzloff MR; Middelberg AP
Vaccine; 2013 Apr; 31(15):1950-5. PubMed ID: 23422147
[TBL] [Abstract][Full Text] [Related]
37. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
Guerino MT; Postol E; Demarchi LM; Martins CO; Mundel LR; Kalil J; Guilherme L
Vaccine; 2011 Oct; 29(46):8250-6. PubMed ID: 21907752
[TBL] [Abstract][Full Text] [Related]
38. Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.
Nordström T; Pandey M; Calcutt A; Powell J; Phillips ZN; Yeung G; Giddam AK; Shi Y; Haselhorst T; von Itzstein M; Batzloff MR; Good MF
J Immunol; 2017 Oct; 199(8):2794-2802. PubMed ID: 28904125
[TBL] [Abstract][Full Text] [Related]
39. Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A
Jin S; Zhang J; Nahar UJ; Huang W; Alharbi NA; Shalash AO; Koirala P; Yang J; Kiong JJE; Khalil ZG; Capon RJ; Stephenson RJ; Skwarczynski M; Toth I; Hussein WM
ACS Infect Dis; 2023 Aug; 9(8):1570-1581. PubMed ID: 37489053
[TBL] [Abstract][Full Text] [Related]
40. M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus.
Skwarczynski M; Kamaruzaman KA; Srinivasan S; Zaman M; Lin IC; Batzloff MR; Good MF; Toth I
Curr Drug Deliv; 2013 Feb; 10(1):39-45. PubMed ID: 22998043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
